A novel and safe approach for treating cognitive disorders

Umecrine Cognition is Swedish pharmaceutical company that is developing a novel class of drugs to treat neurological disorders of the brain, that are caused by a range of underlying diseases and lead to severely impaired cognition and alertness.


Results from an internationally recognized Phase 2 clinical trial indicate that the company's most advanced drug candidate, golexanolone, normalizes brain signalling and improves cognition and alertness in patients with hepatic encephalopathy. Further drug development will initially focus on patient populations with symptoms resulting from chronic liver disease, but the mechanism of action is also relevant in a number of other indications.




Umecrine Cognition to present at two scientific conferences on the importance of neurosteroids in cognitive dysfunction associated with liver disease